MetLife Investment Management LLC Acquires 9,431 Shares of Kenvue Inc. (NYSE:KVUE)

MetLife Investment Management LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 1.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 507,418 shares of the company’s stock after buying an additional 9,431 shares during the period. MetLife Investment Management LLC’s holdings in Kenvue were worth $10,833,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of KVUE. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the period. Finally, Versant Capital Management Inc raised its stake in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on KVUE. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Barclays decreased their price objective on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, April 14th. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Citigroup upped their price target on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Finally, Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $24.42.

Kenvue Stock Up 3.0 %

Kenvue stock opened at $23.42 on Monday. The business has a fifty day moving average price of $22.91 and a 200-day moving average price of $22.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The stock has a market capitalization of $44.93 billion, a price-to-earnings ratio of 44.19, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue’s payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.